{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T08:08:03Z","timestamp":1768032483903,"version":"3.49.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Res"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1038\/pr.2018.24","type":"journal-article","created":{"date-parts":[[2018,3,14]],"date-time":"2018-03-14T17:01:35Z","timestamp":1521046895000},"page":"1067-1074","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Quantitative magnetic resonance imaging assessments of autosomal recessive polycystic kidney disease progression and response to therapy in an animal model"],"prefix":"10.1038","volume":"83","author":[{"given":"Bernadette O","family":"Erokwu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian E","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris A","family":"Flask","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katherine M","family":"Dell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2018,5,2]]},"reference":[{"key":"BFpr201824_CR1","doi-asserted-by":"publisher","first-page":"339","DOI":"10.1053\/j.ackd.2011.05.001","volume":"18","author":"KM Dell","year":"2011","unstructured":"Dell KM . The spectrum of polycystic kidney disease in children. Adv Chronic Kidney Dis 2011;18:339\u2013347.","journal-title":"Adv Chronic Kidney Dis"},{"key":"BFpr201824_CR2","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1007\/s004670050281","volume":"11","author":"S Roy","year":"1997","unstructured":"Roy S, Dillon MJ, Trompeter RS et al. Autosomal recessive polycystic kidney disease: long-term outcome of neonatal survivors. Pediatr Nephrol 1997;11:302\u2013306.","journal-title":"Pediatr Nephrol"},{"key":"BFpr201824_CR3","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.jpeds.2014.06.015","volume":"165","author":"LM Guay-Woodford","year":"2014","unstructured":"Guay-Woodford LM, Bissler JJ, Braun MC et al. Consensus expert recommendations for the diagnosis and management of autosomal recessive polycystic kidney disease: report of an international conference. J Pediatr 2014;165:611\u2013617.","journal-title":"J Pediatr"},{"key":"BFpr201824_CR4","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1038\/nm935","volume":"9","author":"VHn Gattone","year":"2003","unstructured":"Gattone VHn, Wang X, Harris PC et al. Inhibition of renal cystic disease development and progression by a vasopressin V2 receptor antagonist. Nat Med 2003;9:1323\u20131326.","journal-title":"Nat Med"},{"key":"BFpr201824_CR5","doi-asserted-by":"publisher","first-page":"F1243","DOI":"10.1152\/ajprenal.00694.2013","volume":"306","author":"M Sabbatini","year":"2014","unstructured":"Sabbatini M, Russo L, Cappellaio F et al. Effects of combined administration of rapamycin, tolvaptan, and AEZ-131 on the progression of polycystic disease in PCK rats. Am J Physiol Renal Physiol 2014;306:F1243\u2013F1250.","journal-title":"Am J Physiol Renal Physiol"},{"key":"BFpr201824_CR6","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1002\/hep.26140","volume":"58","author":"TV Masyuk","year":"2013","unstructured":"Masyuk TV, Radtke BN, Stroope AJ et al. Pasireotide is more effective than octreotide in reducing hepatorenal cystogenesis in rodents with polycystic kidney and liver diseases. Hepatology 2013;58:409\u2013421.","journal-title":"Hepatology"},{"key":"BFpr201824_CR7","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367:2407\u20132418.","journal-title":"N Engl J Med"},{"key":"BFpr201824_CR8","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1053\/j.ackd.2015.04.001","volume":"22","author":"MT Cramer","year":"2015","unstructured":"Cramer MT, Guay-Woodford LM . Cystic kidney disease: a primer. Adv Chronic Kidney Dis 2015;22:297\u2013305.","journal-title":"Adv Chronic Kidney Dis"},{"key":"BFpr201824_CR9","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.jpeds.2015.12.079","volume":"171","author":"KM Dell","year":"2016","unstructured":"Dell KM, Matheson M, Hartung EA et al. Kidney disease progression in autosomal recessive polycystic kidney disease. J Pediatr 2016;171:196\u2013201.e1.","journal-title":"J Pediatr"},{"key":"BFpr201824_CR10","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1053\/j.ajkd.2005.08.026","volume":"46","author":"WC O'Neill","year":"2005","unstructured":"O'Neill WC, Robbin ML, Bae KT et al. Sonographic assessment of the severity and progression of autosomal dominant polycystic kidney disease: the Consortium of Renal Imaging Studies in Polycystic Kidney Disease (CRISP). Am J Kidney Dis 2005;46:1058\u20131064.","journal-title":"Am J Kidney Dis"},{"key":"BFpr201824_CR11","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1046\/j.1523-1755.2003.00185.x","volume":"64","author":"AB Chapman","year":"2003","unstructured":"Chapman AB, Guay-Woodford LM, Grantham JJ et al. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): the Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort. Kidney Int 2003;64:1035\u20131045.","journal-title":"Kidney Int"},{"key":"BFpr201824_CR12","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1038\/nrneph.2009.214","volume":"6","author":"KT Bae","year":"2010","unstructured":"Bae KT, Grantham JJ . Imaging for the prognosis of autosomal dominant polycystic kidney disease. Nat Rev Nephrol 2010;6:96\u2013106.","journal-title":"Nat Rev Nephrol"},{"key":"BFpr201824_CR13","doi-asserted-by":"publisher","first-page":"369","DOI":"10.2215\/CJN.03780410","volume":"6","author":"MA Cadnapaphornchai","year":"2011","unstructured":"Cadnapaphornchai MA, Masoumi A, Strain JD et al. Magnetic resonance imaging of kidney and cyst volume in children with ADPKD. Clin J Am Soc Nephrol 2011;6:369\u2013376.","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFpr201824_CR14","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1007\/s00247-001-0624-0","volume":"32","author":"FE Avni","year":"2002","unstructured":"Avni FE, Guissard G, Hall M et al. Hereditary polycystic kidney diseases in children: changing sonographic patterns through childhood. Pediatr Radiol 2002;32:169\u2013174.","journal-title":"Pediatr Radiol"},{"key":"BFpr201824_CR15","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1007\/s00330-009-1619-8","volume":"20","author":"X Xu","year":"2010","unstructured":"Xu X, Fang W, Ling H et al. Diffusion-weighted MR imaging of kidneys in patients with chronic kidney disease: initial study. Eur Radiol 2010;20:978\u2013983.","journal-title":"Eur Radiol"},{"key":"BFpr201824_CR16","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1016\/j.crad.2014.06.011","volume":"69","author":"J Zhao","year":"2014","unstructured":"Zhao J, Wang ZJ, Liu M et al. Assessment of renal fibrosis in chronic kidney disease using diffusion-weighted MRI. Clin Radiol 2014;69:1117\u20131122.","journal-title":"Clin Radiol"},{"key":"BFpr201824_CR17","doi-asserted-by":"publisher","first-page":"e113469","DOI":"10.1371\/journal.pone.0113469","volume":"9","author":"Z Zheng","year":"2014","unstructured":"Zheng Z, Shi H, Zhang J et al. Renal water molecular diffusion characteristics in healthy native kidneys: assessment with diffusion tensor MR imaging. PLoS ONE 2014;9:e113469.","journal-title":"PLoS ONE"},{"key":"BFpr201824_CR18","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1038\/ki.2013.361","volume":"85","author":"JL Zhang","year":"2014","unstructured":"Zhang JL, Morrell G, Rusinek H et al. New magnetic resonance imaging methods in nephrology. Kidney Int 2014;85:768\u2013778.","journal-title":"Kidney Int"},{"key":"BFpr201824_CR19","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1159\/000333044","volume":"34","author":"L Lu","year":"2011","unstructured":"Lu L, Sedor JR, Gulani V et al. Use of diffusion tensor MRI to identify early changes in diabetic nephropathy. Am J Nephrol 2011;34:476\u2013482.","journal-title":"Am J Nephrol"},{"key":"BFpr201824_CR20","doi-asserted-by":"publisher","first-page":"e0164193","DOI":"10.1371\/journal.pone.0164193","volume":"11","author":"MH Ta","year":"2016","unstructured":"Ta MH, Schwensen KG, Foster S et al. Effects of TORC1 inhibition during the early and established phases of polycystic kidney disease. PLoS ONE 2016;11:e0164193.","journal-title":"PLoS ONE"},{"key":"BFpr201824_CR21","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1016\/j.kint.2017.05.024","volume":"92","author":"M Franke","year":"2017","unstructured":"Franke M, Baessler B, Vechtel J et al. Magnetic resonance T2 mapping and diffusion-weighted imaging for early detection of cystogenesis and response to therapy in a mouse model of polycystic kidney disease. Kidney Int 2017;92:1544\u20131554.","journal-title":"Kidney Int"},{"key":"BFpr201824_CR22","doi-asserted-by":"publisher","first-page":"e12196","DOI":"10.14814\/phy2.12196","volume":"2","author":"MH Ta","year":"2014","unstructured":"Ta MH, Rao P, Korgaonkar M et al. Pyrrolidine dithiocarbamate reduces the progression of total kidney volume and cyst enlargement in experimental polycystic kidney disease. Physiol Rep 2014;2:e12196.","journal-title":"Physiol Rep"},{"key":"BFpr201824_CR23","doi-asserted-by":"publisher","first-page":"258","DOI":"10.1124\/jpet.114.213256","volume":"349","author":"M Aihara","year":"2014","unstructured":"Aihara M, Fujiki H, Mizuguchi H et al. Tolvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing increases in kidney volume and renal injury. J Pharmacol Exp Ther 2014;349:258\u2013267.","journal-title":"J Pharmacol Exp Ther"},{"key":"BFpr201824_CR24","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1038\/ng833","volume":"30","author":"CJ Ward","year":"2002","unstructured":"Ward CJ, Hogan MC, Rossetti S et al. The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein. Nat Genet 2002;30:259\u2013269.","journal-title":"Nat Genet"},{"key":"BFpr201824_CR25","doi-asserted-by":"publisher","first-page":"2449","DOI":"10.1007\/s00467-010-1621-z","volume":"25","author":"M Goto","year":"2010","unstructured":"Goto M, Hoxha N, Osman R et al. The renin-angiotensin system and hypertension in autosomal recessive polycystic kidney disease. Pediatr Nephrol 2010;25:2449\u20132457.","journal-title":"Pediatr Nephrol"},{"key":"BFpr201824_CR26","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1053\/j.gastro.2006.12.039","volume":"132","author":"TV Masyuk","year":"2007","unstructured":"Masyuk TV, Masyuk AI, Torres VE et al. Octreotide inhibits hepatic cystogenesis in a rodent model of polycystic liver disease by reducing cholangiocyte adenosine 3',5'-cyclic monophosphate. Gastroenterology 2007;132:1104\u20131116.","journal-title":"Gastroenterology"},{"key":"BFpr201824_CR27","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1002\/ar.21166","volume":"293","author":"SB Mason","year":"2010","unstructured":"Mason SB, Liang Y, Sinders RM et al. Disease stage characterization of hepatorenal fibrocystic pathology in the PCK rat model of ARPKD. Anat Rec 2010;293:1279\u20131288.","journal-title":"Anat Rec"},{"key":"BFpr201824_CR28","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1002\/mrm.1910030602","volume":"3","author":"J Hennig","year":"1986","unstructured":"Hennig J, Nauerth A, Friedburg H . RARE imaging: a fast imaging method for clinical MR. Magn Reson Med 1986;3:823\u2013833.","journal-title":"Magn Reson Med"},{"key":"BFpr201824_CR29","doi-asserted-by":"publisher","first-page":"972","DOI":"10.2215\/CJN.07141009","volume":"5","author":"M Gunay-Aygun","year":"2010","unstructured":"Gunay-Aygun M, Font-Montgomery E, Lukose L et al. Correlation of kidney function, volume and imaging findings, and PKHD1 mutations in 73 patients with autosomal recessive polycystic kidney disease. Clin J Am Soc Nephrol 2010;5:972\u2013984.","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFpr201824_CR30","doi-asserted-by":"publisher","first-page":"1771","DOI":"10.1007\/s00467-012-2370-y","volume":"28","author":"MC Liebau","year":"2013","unstructured":"Liebau MC, Serra AL . Looking at the (w)hole: magnet resonance imaging in polycystic kidney disease. Pediatr Nephrol 2013;28:1771\u20131783.","journal-title":"Pediatr Nephrol"},{"key":"BFpr201824_CR31","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/jmri.25625","volume":"46","author":"TJ Fraum","year":"2017","unstructured":"Fraum TJ, Ludwig DR, Bashir MR et al. Gadolinium-based contrast agents: a comprehensive risk assessment. J Magn Reson Imaging 2017;46:338\u2013353.","journal-title":"J Magn Reson Imaging"},{"key":"BFpr201824_CR32","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1111\/j.1523-1755.2005.00395.x","volume":"68","author":"P Ruggenenti","year":"2005","unstructured":"Ruggenenti P, Remuzzi A, Ondei P et al. Safety and efficacy of long-acting somatostatin treatment in autosomal-dominant polycystic kidney disease. Kidney Int 2005;68:206\u2013216.","journal-title":"Kidney Int"},{"key":"BFpr201824_CR33","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1002\/nbm.3442","volume":"29","author":"Y Gao","year":"2016","unstructured":"Gao Y, Erokwu BO, DeSantis DA et al. Initial evaluation of hepatic T1 relaxation time as an imaging marker of liver disease associated with autosomal recessive polycystic kidney disease (ARPKD). NMR Biomed 2016;29:84\u201389.","journal-title":"NMR Biomed"},{"key":"BFpr201824_CR34","doi-asserted-by":"publisher","first-page":"e0163063","DOI":"10.1371\/journal.pone.0163063","volume":"11","author":"JA Nieto","year":"2016","unstructured":"Nieto JA, Yamin MA, Goldberg ID et al. An empirical biomarker-based calculator for cystic index in a model of autosomal recessive polycystic kidney disease-the Nieto-Narayan formula. PLoS ONE 2016;11:e0163063.","journal-title":"PLoS ONE"},{"key":"BFpr201824_CR35","doi-asserted-by":"publisher","first-page":"576","DOI":"10.2215\/CJN.08300815","volume":"11","author":"Y Kim","year":"2016","unstructured":"Kim Y, Ge Y, Tao C et al. Automated segmentation of kidneys from MR images in patients with autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2016;11:576\u2013584.","journal-title":"Clin J Am Soc Nephrol"},{"key":"BFpr201824_CR36","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1002\/nbm.3262","volume":"28","author":"Y Gao","year":"2015","unstructured":"Gao Y, Chen Y, Ma D et al. Preclinical MR fingerprinting (MRF) at 7\u2009T: effective quantitative imaging for rodent disease models. NMR Biomed 2015;28:384\u2013394.","journal-title":"NMR Biomed"},{"key":"BFpr201824_CR37","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1038\/nature11971","volume":"495","author":"D Ma","year":"2013","unstructured":"Ma D, Gulani V, Seiberlich N et al. Magnetic resonance fingerprinting. Nature 2013;495:187\u2013192.","journal-title":"Nature"},{"key":"BFpr201824_CR38","doi-asserted-by":"publisher","first-page":"2564","DOI":"10.1681\/ASN.2016101089","volume":"28","author":"GR Morrell","year":"2017","unstructured":"Morrell GR, Zhang JL, Lee VS . Magnetic resonance imaging of the fibrotic kidney. J Am Soc Nephrol 2017;28:2564\u20132570.","journal-title":"J Am Soc Nephrol"}],"container-title":["Pediatric Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/pr201824.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/pr201824","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/doifinder\/10.1038\/pr.2018.24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"http:\/\/www.nature.com\/articles\/pr201824.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:05:10Z","timestamp":1684616710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/pr201824"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["BFpr201824"],"URL":"https:\/\/doi.org\/10.1038\/pr.2018.24","relation":{},"ISSN":["0031-3998","1530-0447"],"issn-type":[{"value":"0031-3998","type":"print"},{"value":"1530-0447","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"28 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}